| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G21G2001-0094 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G21G1-001 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2015-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017528512-A |
| titleOfInvention |
Astatine-211 [At-211] Automated Process Platform for Radiopharmaceutical Production |
| abstract |
Systems and methods for automated production of astatine-211 labeled molecules are described. The present invention represents an important advantage in the preparation of At-211 radiopharmaceuticals, including better reproducibility, reduced production times and increased radiation safety. The present invention also allows for routine automated synthesis of radiopharmaceuticals in a clinical setting in connection with or in close proximity to a cyclotron device capable of producing radionuclides. [Selection] Figure 5 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7237366-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2019176585-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019131998-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11684683-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2019131998-A1 |
| priorityDate |
2014-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |